- Home
- »
- Biotechnology
- »
-
Cell Therapy Technologies Market Size Report, 2026-2033GVR Report cover
![Cell Therapy Technologies Market (2026 - 2033)Report]()
Cell Therapy Technologies Market (2026 - 2033)
Size, Share & Trends Analysis Report By Product (Raw Materials, Instruments), By Workflow (Separation, Expansion), By Cell Type (T-cells, Stem Cells), By End Use, By Region, And Segment Forecasts
Market Size, 2025
$7.7BMarket Estimate, 2026
$9.0BMarket Forecast, 2033
$28.9BCAGR, 2026–2033
18.1%Cell Therapy Technologies Market Summary
The global cell therapy technologies market size was valued at USD 7.7 billion in 2025 and is projected to grow from USD 9.0 billion in 2026 to USD 28.9 billion by 2033, at a CAGR of 18.1% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.2% in 2025. The industry is experiencing significant growth, driven by advancements in personalized medicine and substantial investments from pharmaceutical giants.
Key Market Trends & Insights
- By product: consumables & accessories segment held the largest revenue share of over 42.7% in 2025.
- By workflow: separation segment held the largest revenue share of over 35.0% in 2025, and it is expected to grow with the fastest CAGR over the forecast period.
- By cell type: T-cells segment held the largest revenue share of over 57.7% in 2025, and it is expected to grow with the fastest CAGR over the forecast period.
- By end use: biopharmaceutical & pharmaceutical companies segment held the largest revenue share of over 53.2% in 2025.
Regional Highlights
- Largest regional market: North America (40.2% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025.
Market Size & Forecast
- Market size in 2025: USD 7.7 Billion
- Estimated market size in 2026: USD 9.0 Billion
- Projected market size by 2033: USD 28.9 Billion
- CAGR (2026-2033): 18.1%
The increasing focus on tailoring treatments to individual patient needs has led to the development of innovative cell-based therapies, enhancing treatment efficacy and patient outcomes. This personalized approach is particularly evident in the rise of CAR-T cell therapies, which modify a patient's cells to combat diseases like cancer. Companies such as Autolus are at the forefront of developing new CAR-T cell therapies like Aucatzyl for acute lymphoblastic leukemia, which has recently received approval from the U.S. FDA.
The COVID-19 pandemic has further underscored the importance of rapid and adaptable therapeutic development. The success of mRNA vaccines during the pandemic has accelerated interest in applying similar technologies to cell therapies. Companies like BioNTech and Moderna, known for their COVID-19 vaccines, are now focusing on personalized mRNA cancer vaccines to bolster the immune system's ability to fight the disease. This shift highlights the versatility of mRNA technology and its potential to revolutionize cell-based treatments.
Recent company initiatives reflect a strategic emphasis on expanding cell therapy capabilities. For instance, in November 2024, Roche's acquisition of Poseida Therapeutics for up to USD 1.5 billion aims to enhance its pipeline in oncology, immunology, and neurology cell therapies. Poseida specializes in CAR-T cell therapies, and this acquisition is expected to facilitate the development of next-generation off-the-shelf CAR-T treatments that are scalable, potent, and safer.
Similarly, in February 2024, AstraZeneca's acquisition of Gracell Biotechnologies for up to USD 1.2 billion signifies a strategic move to advance cell therapies. Gracell, based in Shanghai, is critical for AstraZeneca's goal to launch 20 new medicines by 2030, focusing on innovative cell therapy solutions. This acquisition highlights the growing importance of cell therapy technologies in the pharmaceutical industry's future strategies.
Market Dynamics
The cell therapy technologies market is witnessing significant growth, driven by the rising adoption of cell-based therapies in oncology, regenerative medicine, and the treatment of autoimmune diseases. Increasing investments in biotechnology research, expanding clinical trial activity, and growing demand for personalized medicine are accelerating the adoption of advanced cell processing, cell expansion, gene editing, and cryopreservation technologies. Moreover, continuous technological advancements, a strong pipeline of cell therapies, and increasing collaborations among biopharmaceutical companies, research institutions, and technology providers are expected to support market growth over the forecast period.
The increasing number of regulatory approvals for CAR-T cell therapies and other advanced cell-based treatments is a major driver for the cell therapy technologies market. As more therapies progress from clinical development to commercialization, demand is rising for technologies involved in cell isolation, activation, genetic modification, expansion, cryopreservation, and quality control. Approved therapies require highly standardized and scalable manufacturing processes, encouraging biopharmaceutical companies and contract manufacturers to invest in advanced cell therapy platforms. Moreover, the expanding use of cell therapies across hematological malignancies, solid tumors, autoimmune disorders, and rare diseases is creating sustained demand for innovative cell processing and manufacturing technologies.
For instance, in June 2025, the U.S. FDA removed the Risk Evaluation and Mitigation Strategy (REMS) requirements for approved BCMA- and CD19-directed CAR-T cell therapies, reflecting increased confidence in the safety and clinical management of these treatments and facilitating broader patient access. In addition, the FDA’s growing list of advanced therapy approvals, including CAR-T products and regenerative medicine therapies, continues to strengthen the commercial landscape for cell-based treatments. These developments are expected to accelerate manufacturing capacity expansion and adoption of next-generation cell therapy technologies, supporting market growth over the forecast period.
The development of cell therapies requires extensive preclinical research, manufacturing process optimization, and multi-phase clinical trials to establish safety, efficacy, and product consistency. Unlike conventional therapeutics, cell-based treatments involve complex procedures such as cell isolation, expansion, modification, and quality assessment, all of which must meet stringent regulatory standards. These requirements significantly increase development timelines and costs, delaying product commercialization and limiting the speed of market expansion.
In addition, clinical trials for cell therapies are often more challenging due to personalized treatment approaches, specialized patient populations, and the need for long-term safety and efficacy monitoring. Regulatory agencies require comprehensive data on manufacturing reproducibility, product potency, and clinical outcomes, resulting in lengthy review and approval processes. The need for specialized infrastructure, skilled personnel, and extensive compliance measures further increases operational complexity, creating barriers for developers and restraining growth in the cell therapy technologies market.
Market Concentration & Characteristics
The cell therapy technologies industry is set for strong growth, driven by advances in automation, bioprocessing, and genetic engineering. Growing demand for personalized medicine, regenerative treatments, and cancer therapies is boosting investment. Supportive regulations and improved manufacturing processes are also helping companies scale up production and bring new cell therapies to market faster.
The industry is growing steadily, with moderate collaboration activity among industry players. Key drivers include the rising demand for advanced therapies, automation in manufacturing, and increased R&D investments. Strategic partnerships between biopharma companies, CMOs, and tech firms are helping improve efficiency, scalability, and innovation in cell therapy development and production. In June 2023, StemCyte partnered with a leading U.S. immune cell therapy company to supply raw materials for the development of allogeneic modified cell therapies.
Regulations have positively influenced the cell therapy technologies market by ensuring manufacturing quality, safety, and standardization. Clear guidelines have accelerated product approvals, encouraged investments, and supported automated processing and scalable production innovation. This regulatory support is helping companies bring advanced cell therapies to market more efficiently.
The cell therapy technologies industry has seen moderate growth in product expansion, driven by advancements in automation, bioprocessing, and raw material development. Increasing demand for efficient manufacturing solutions and innovations in cell expansion, separation, and cryopreservation technologies are shaping the industry’s growth.
The cell therapy technologies market is expanding gradually across regions, driven by growing demand, supportive regulations, and new investments. Companies are setting up new facilities, forming partnerships, and improving production capabilities to enter new markets and meet the rising need for advanced cell therapies.
Analyst Perspective
The cell therapy technologies market is poised for significant growth, driven by the increasing number of cell therapy clinical trials, rising approvals of CAR-T and other advanced cell therapies, and growing investments in regenerative medicine. Demand for advanced cell processing, cell culture, cell sorting, and raw-material technologies is increasing as developers seek scalable, efficient manufacturing workflows. Continuous advancements in automation, closed-system processing, and GMP-compliant manufacturing platforms are improving production efficiency and product quality. As the commercialization of cell-based therapies accelerates globally, technology providers are focusing on innovation, workflow integration, and capacity expansion to support evolving therapeutic development and manufacturing needs.
Product Insights
Based on product, the consumables & accessories segment held the largest revenue share of over 42.7% in 2025, driven by the high demand for culture media, reagents, and growth factors essential for cell therapy research and production. The increasing adoption of cell-based therapies, advancements in bioprocessing techniques, and the rising number of clinical trials have further fueled market growth. Additionally, the recurring nature of consumable usage in manufacturing and research makes this segment a key revenue driver in the industry.
The software segment in the cell therapy technologies market is expected to grow at the highest CAGR of 19.88% from 2025 to 2030. The increasing need for data management, automation, and regulatory compliance in cell therapy development and manufacturing drives this growth. Advanced software solutions help streamline workflow automation, real-time monitoring, and quality control, ensuring efficiency and scalability. As the industry moves toward digitalization and process standardization, the demand for specialized software to support clinical trials, manufacturing, and supply chain management continues to rise.
Workflow Insights
Based on workflow, the separation segment held the largest revenue share of over 35.0% in 2025, and it is expected to grow with the fastest CAGR over the forecast period. The need for greater efficiency, scalability, and cost reduction in cell therapy manufacturing drives this growth. Automating key processes like cell expansion and separation is a major factor behind this trend. For example, in February 2024, Multiply Labs and Thermo Fisher Scientific expanded their partnership to automate these steps, improving workflows, efficiency, and production speed while ensuring quality control. This automation is expected to help scale manufacturing, lower costs, and meet the rising demand for cell therapies.
The expansion segment is also set for strong growth, driven by the need for scalable and automated manufacturing to enhance the production and effectiveness of cell and gene therapies, particularly for solid tumor treatments. In September 2024, Xcell Biosciences strengthened its partnership with Labcorp by launching AVATAR Foundry, a platform designed to automate large-scale cell and gene therapy production. This initiative aims to make cell therapies more scalable and potent, addressing the increasing demand for efficient manufacturing in this rapidly growing market.
Cell Type Insights
Based on cell type, the T-cells segment held the largest revenue share of over 57.7% in 2025, and it is expected to grow with the fastest CAGR over the forecast period. This growth is driven by the increasing adoption of T-cell therapies, such as CAR-T and TCR-T therapies, for treating cancer, autoimmune diseases, and infectious diseases. Advances in genetic engineering, cell expansion, and automation are further boosting demand. As research and clinical applications expand, the need for advanced technologies and raw materials to support T-cell therapy development and manufacturing continues to rise.
The stem cells segment is expected to grow strongly in the cell therapy technologies market, driven by their expanding use in regenerative medicine, tissue repair, and autoimmune disease treatments. Increasing clinical research, advancements in stem cell banking, and improved bioprocessing techniques further fuel demand. Additionally, the rising prevalence of degenerative diseases and supportive regulatory frameworks encourage investments in stem cell-based therapies, boosting market expansion.
End Use Insights
Based on end use, the biopharmaceutical & pharmaceutical companies segment held the largest revenue share of over 53.2% in 2025, driven by their growing focus on cell therapies for diseases like cancer, autoimmune disorders, and degenerative conditions. These companies invest heavily in research, development, and commercialization, increasing demand for high-quality raw materials needed in cell therapy production. For example, in September 2023, Novo Nordisk invested USD 136 million to build a cell therapy manufacturing facility in Denmark at the Technical University of Denmark (DTU). This facility will focus on producing stem cell therapies for early-stage clinical trials.
Meanwhile, the CMOs & CROs segment is expected to grow the fastest in the coming years. The rising trend of outsourcing has fueled this growth, as biopharmaceutical companies seek specialized expertise and cost-effective solutions for cell therapy development and production. CMOs and CROs provide end-to-end services, from research to manufacturing, allowing companies to focus on innovation while reducing operational costs and risks. This shift has significantly increased demand for key raw materials like growth factors and culture media. As investments in cell therapy R&D continue to rise, CMOs and CROs will support the industry’s expansion.
Regional Insights
North America dominated the cell therapy technologies market with the largest revenue share of 40.2% in 2025, driven by the rising cases of cancer, diabetes, and heart diseases. The growing demand for advanced cell-based treatments has increased the need for essential raw materials, software, and instruments. The region's strong healthcare system and clear regulations have made it easier for companies to develop and bring cell therapies to the market. This supportive environment has attracted significant investments from governments and private companies, boosting research and innovation in the field.
U.S. Cell Therapy Technologies Market Trends
The cell therapy technologies market in the U.S. held the largest share in the North America region in 2025.
Europe Cell Therapy Technologies Market Trends
The cell therapy technologies market in Europe is driven by the growing demand for advanced therapies and increasing investment in cell biology research. The region has seen significant growth in recent years as the industry continues to develop.
The UK cell therapy technologies market is expanding quickly as more cell-based treatments are used for cancer, autoimmune disorders, and genetic diseases. Advances in regenerative medicine and personalized therapies drive demand for key raw materials like growth factors, cytokines, and cell culture media, essential for developing and producing cell therapies.
The cell therapy technologies market in Germany is growing rapidly due to the rising demand for advanced regenerative medicine and cancer care treatments.
Asia Pacific Cell Therapy Technologies Market Trends
The cell therapy technologies market in Asia Pacific is expected to grow at the fastest CAGR of 18.92% from 2025-2030, driven by rising chronic and degenerative diseases like cancer, heart diseases, and neurological disorders. This has increased the demand for cell therapies and the raw materials needed for their production. Additionally, supportive regulations in countries like China and India are helping to accelerate market growth.
China cell therapy technologies market is set for rapid growth, driven by the adoption of automated systems that improve production efficiency, data monitoring, and support for clinical trials and R&D. For example, in October 2024, Sino-Biocan (Shanghai) Biotech Ltd launched the WUKONG Automated Cell Processing System, which streamlines the entire process from blood collection to cell drug production. This closed-loop, real-time monitoring system enhances efficiency and supports the development of new cell therapies.
The cell therapy technologies market in Japan is driven by the use of robotics and pharmaceutical technologies to improve production efficiency, quality, and cost-effective scaling. For example, in May 2024, YASKAWA ELECTRIC CORPORATION and Astellas Pharma partnered to develop a cell therapy platform that integrates robotics with pharmaceutical processes, helping research institutions and startups transition from lab research to large-scale manufacturing while ensuring high quality and stability.
Key Cell Therapy Technologies Company Insights
Key players operating in the cell therapy technologies market are undertaking various initiatives to strengthen their market presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are playing a key role in propelling market growth.
Key Cell Therapy Technologies Companies:
The following are the leading companies in the cell therapy technologies market.
-
Danaher Corporation
-
Merck KGaA
-
Thermo Fisher Scientific Inc.
-
Lonza Group
-
Sartorius AG
-
Promega
-
BD
-
Miltenyi Biotec
-
CellPort Software
-
Shimadzu
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Players (Danaher Corporation, Merck KGaA, Thermo Fisher Scientific, Lonza Group, etc.)
- Expand market presence through strategic collaborations, manufacturing capacity expansions, and investments in cell & gene therapy workflow automation and commercialization.
- Broad portfolios spanning instruments, consumables, reagents, software, and bioprocessing solutions that support end-to-end cell therapy development and manufacturing.
- Significant capital investment requirements and exposure to evolving regulatory standards and manufacturing complexities.
Emerging Players (CellPort Software, Miltenyi Biotec, Shimadzu)
- Focus on specialized digital solutions and software platforms that improve cell therapy workflow management, data integration, and operational efficiency.
- Strong specialization in software-driven workflow optimization and digitalization of cell therapy processes.
- Limited scale and market presence compared to established life science and bioprocessing companies.
Recent Developments
-
In December 2024, BioCentriq invested USD 12 million in a new cell therapy manufacturing facility in Princeton, NJ, which will also be its headquarters. This expansion will strengthen its cell therapy development and production capabilities.
-
In September 2024, Vertex Pharmaceuticals partnered with Lonza in a long-term supply agreement to manufacture Casgevy, a gene-edited cell therapy for sickle cell disease and β-thalassemia.
-
In December 2023, Miltenyi Biotec and Replay signed a licensing and manufacturing deal to develop GMP-compliant TCR-NK cell therapies targeting PRAME, a tumor-associated neoantigen, advancing cancer immunotherapy.
Cell Therapy Technologies Market Report Scope
Report Attribute
Details
Market size in 2025
USD 7.7 billion
Estimated market size in 2026
USD 9.0 billion
Projected market size by 2033
USD 28.9 billion
Growth rate
CAGR of 18.1% from 2026 to 2033
Historical data
2021 - 2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million, and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Product, workflow, cell type, end use, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Norway, Denmark, Sweden, China, Japan, India, South Korea, Australia, Thailand, Brazil, Argentina, Saudi Arabia, South Africa, UAE, Kuwait
Key companies profiled
Danaher Corporation; Merck KGaA; Thermo Fisher Scientific Inc.; Lonza Group; Sartorius AG; Promega; BD; Miltenyi Biotec; CellPort Software; Shimadzu
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Cell Therapy Technologies Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cell therapy technologies market report based on product, workflow, cell type, end use, and region:
-
Product Outlook (Revenue, USD Million, 2021 - 2033)
-
Raw Materials
-
Media
-
Sera
-
Cell Culture Supplements
-
Antibodies
-
Reagents & Buffers
-
Others
-
-
Instruments
-
Cell Therapy Processing Systems
-
Cell Culture Systems
-
Cell Sorting & Separation Systems
-
Other Instruments
-
-
Software
-
Consumables & Accessories
-
-
Workflow Outlook (Revenue, USD Million, 2021 - 2033)
-
Separation
-
Expansion
-
Apheresis
-
Fill- Finish
-
Cryopreservation
-
Others
-
-
Cell Type Outlook (Revenue, USD Million, 2021 - 2033)
-
T-cells
-
Stem Cells
-
Other Cells
-
-
End Use Outlook (Revenue, USD Million, 2021 - 2033)
-
Biopharmaceutical & Biotechnology Companies
-
CMOs & CROs
-
Others
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
China
-
Japan
-
India
-
South Korea
-
Australia
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
MEA
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Research Methodology
The cell therapy technologies market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each cell therapy technologies segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment- Product
Revenue Capture Definition
Raw Materials
Revenue generated from critical inputs used throughout cell therapy development and manufacturing workflows. This segment includes media, sera, cell culture supplements, antibodies, reagents & buffers, and other ancillary materials required for cell isolation, activation, expansion, differentiation, preservation, and quality control processes. These products play an essential role in maintaining cell viability, functionality, and manufacturing consistency across autologous and allogeneic cell therapy production.
Instruments
This segment captures income from equipment used to automate, monitor, and optimize cell therapy manufacturing operations. The category includes cell therapy processing systems for closed, scalable manufacturing, cell culture systems for cell growth and expansion, cell sorting & separation systems for target cell isolation and enrichment, and other instruments for processing, monitoring, quality assurance, and workflow standardization.
Software
Revenue originates from software platforms used for process monitoring, workflow management, manufacturing execution, batch tracking, quality control, data analysis, and regulatory compliance throughout cell therapy production. These solutions help improve operational efficiency, traceability, and process reproducibility across manufacturing environments.
Consumables & Accessories
Market value stems from single-use products and supporting accessories utilized during cell therapy manufacturing and processing workflows. This includes tubing sets, culture vessels, bags, filters, connectors, cartridges, containers, and other disposable components designed to support sterile processing while minimizing contamination risks.
Segment- Workflow
Revenue Capture Definition
Separation
Revenue derived from technologies and materials used to isolate, enrich, and purify target cell populations from biological samples. These workflows are critical for obtaining high-quality cells required for downstream therapeutic manufacturing processes.
Expansion
This segment reflects earnings from products and technologies used to stimulate cell proliferation and increase cell yields while maintaining desired cellular characteristics. Expansion processes are essential for producing sufficient cell quantities for clinical and commercial applications.
Apheresis
Revenue originates from technologies and consumables used to collect specific blood components and target cells from donors or patients. Apheresis serves as a key starting point for many autologous and allogeneic cell therapy manufacturing workflows.
Fill-Finish
This category captures income from technologies that support the final formulation, packaging, dispensing, and preparation of cell therapy products prior to storage, transportation, or patient administration.
Cryopreservation
Market value is generated from products and systems used to preserve cells at ultra-low temperatures while maintaining viability and functionality for future therapeutic use. These workflows are critical for storage, transportation, and supply chain management of cell therapies.
Others
Includes revenue from additional cell therapy workflow technologies supporting cell activation, modification, harvesting, washing, quality testing, and other specialized manufacturing operations.
Segment- Cell Type
Revenue Capture Definition
T-cells
Revenue generated from technologies, materials, and systems used in the isolation, engineering, activation, expansion, preservation, and manufacturing of T-cell-based therapies. This segment includes applications such as CAR-T, TCR-T, and other immune cell therapies targeting cancer and immune-related disorders.
Stem Cells
This segment captures income from products utilized in stem cell isolation, culture, expansion, differentiation, preservation, and therapeutic development. Applications span regenerative medicine, tissue engineering, and treatment of degenerative and genetic disorders.
Other Cells
Revenue stems from technologies supporting the development and manufacturing of cell therapies based on alternative cell types, including natural killer (NK) cells, dendritic cells, macrophages, induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and other emerging therapeutic cell populations.
Segment- End Use
Revenue Capture Definition
Biopharmaceutical & Biotechnology Companies
Revenue generated from the adoption of cell therapy technologies by organizations engaged in cell therapy discovery, process development, clinical manufacturing, commercialization, and advanced therapy research. These companies utilize technologies across the entire cell therapy production lifecycle.
CMOs & CROs
This segment represents income from contract manufacturing organizations (CMOs), contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs) that provide outsourced development, analytical testing, process optimization, manufacturing, and regulatory support services for cell therapy developers.
Others
Revenue originates from academic research institutes, hospitals, cell therapy centers, government organizations, and non-profit research entities involved in translational research, clinical studies, and development of next-generation cell-based therapies.
Estimation Model
Approach
Description
Top-Down (Commodity Flow Analysis)
Market size was estimated by analyzing revenues of key cell therapy technology providers offering cell processing systems, cell culture systems, cell sorting platforms, and critical raw materials. Data from company reports, industry databases, and primary interviews were used to assess revenues and derive the overall market value.
Parent Market (Parent Market & Penetration-Based Analysis)
The cell therapy technologies market was evaluated within the broader cell therapy market. Adoption rates of enabling technologies across autologous and allogeneic cell therapy development, clinical trials, commercial manufacturing, and translational research activities were analyzed to estimate the addressable market and segment-level opportunities.
Segmentation (Country-Level Segment Share Modeling)
Market shares for product, workflow, cell type, and end-use segments were derived using country-specific cell therapy clinical trial activity, regulatory approvals, biopharmaceutical manufacturing infrastructure, research funding, and adoption of advanced cell processing technologies. Weighted-average calculations were used to determine regional and global segment distributions.
Validation (Data Triangulation & Validation Model)
Market estimates were validated through triangulation of secondary research, primary interviews, company-level revenue assessments, cell therapy pipeline analysis, manufacturing capacity evaluations, and end-user demand trends to ensure consistency and accuracy across all market segments and geographies.
Forecasting (Forecasting & CAGR Modeling)
Market forecasts were developed using historical trends in cell therapy development, growth in CAR-T and other advanced cell therapies, expansion of cell therapy manufacturing capacity, increasing clinical trial activity, technological advancements in cell processing platforms, and investments in regenerative medicine. Regression-based analysis and trend modeling were applied to project future market growth and CAGR.
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Workflow & Technology Cross-Segmentation Analysis for Cell Therapy Manufacturing
Detailed cross-segmentation analysis across cell therapy workflows (separation, expansion, apheresis, cryopreservation, and fill-finish) and technology platforms, including cell therapy processing systems, cell culture systems, cell sorting & separation systems, software, consumables, and raw materials. Assessment of technology adoption by cell type (T-cells, stem cells, and other cells) and end-user groups.
Enables clients to identify high-growth workflow-technology combinations, evaluate process bottlenecks, benchmark technology penetration across cell therapy manufacturing stages, and prioritize investments in the most commercially attractive technology segments.
Competitive Benchmarking & Cell Therapy Technology Provider Assessment
Comprehensive benchmarking of leading cell therapy technology providers across product portfolio strength, automation capabilities, manufacturing scalability, geographic presence, strategic partnerships, cell processing expertise, cell culture technologies, and cell sorting/separation capabilities. Includes evaluation of innovation pipelines and commercial positioning.
Supports competitive intelligence, identification of partnership and acquisition opportunities, assessment of technology differentiation, and development of market entry and expansion strategies within the rapidly evolving cell therapy ecosystem.
Regional Demand & Commercialization Opportunity Assessment
Customized regional and country-level analysis covering North America, Europe, Asia Pacific, Latin America, and MEA, with detailed evaluation of cell therapy clinical trial activity, manufacturing infrastructure, regulatory landscape, biopharma investments, CDMO/CRO ecosystem maturity, and demand for cell therapy technologies across major markets.
Helps clients identify emerging manufacturing hubs, assess country-level commercialization potential, prioritize geographic expansion, and align investment strategies with regions demonstrating the highest cell therapy development and manufacturing activity.
Frequently Asked Questions About This Report
Some of the key players operating in the market include, Danaher Corporation; Merck KGaA; Thermo Fisher Scientific Inc.; Lonza Group; Sartorius AG; Promega; BD; Miltenyi Biotec; CellPort Software; Shimadzu
The market growth can be primarily attributed to advancements in cell-based therapy development and increased funding and investment.
The separation segment held the largest share of 35.0% in 2025 and is also expected to grow with the fastest CAGR throughout the forecast period.
The T-cells segment held the largest share of 57.7% in 2025 and is also expected to grow with the fastest CAGR throughout the forecast period.
The biopharmaceutical & pharmaceutical companies segment held the largest share of 53.2% in 2025.
North America dominated with a 40.2% revenue share in 2025.
The global cell therapy technologies market size was estimated at USD 7.7 billion in 2025 and is expected to reach USD 9.0 billion in 2026.
The global cell therapy technologies market is expected to grow at a compound annual growth rate of 18.1% from 2026 to 2033 to reach USD 28.9 billion by 2033.
The consumables & accessories segment held the largest share of 42.7% in 2025. The growth of the consumables segment can be attributed to their high demand and recurring usage in the cell therapy development.
About the Author(s)
Biotechnology Research Team
Healthcare · BiotechnologyThis report was authored by the biotechnology research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the biotechnology segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs — add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
